{"id": "article-155737_0", "title": "Voclosporin -- Continuing Education Activity", "content": "Voclosporin, a novel immunosuppressive medication, is approved for treating and managing lupus nephritis (LN) within the class of calcineurin inhibitors (CNIs). LN is a common manifestation of systemic lupus erythematosus (SLE), an autoimmune disease affecting various organs. Approximately 40% of SLE patients may develop LN. The primary goal of LN treatment is to preserve kidney function, reduce mortality, and improve the patient's quality of life while minimizing treatment-related adverse events. A timely response to therapy, as indicated by a reduction in proteinuria, may predict long-term outcomes, including the risk of SLE flares, end-stage kidney disease, and mortality. In the United States, voclosporin received FDA approval in 2021 for treating active LN in adults, combined with background immunosuppressive therapy. This CME activity overviews the indications, actions, and contraindications for voclosporin. It also emphasizes the mechanism of action, adverse event profile, and key factors such as dosing, pharmacokinetics, contraindications, and monitoring that are essential for healthcare team members involved in treating patients with lupus nephritis using voclosporin.", "contents": "Voclosporin -- Continuing Education Activity. Voclosporin, a novel immunosuppressive medication, is approved for treating and managing lupus nephritis (LN) within the class of calcineurin inhibitors (CNIs). LN is a common manifestation of systemic lupus erythematosus (SLE), an autoimmune disease affecting various organs. Approximately 40% of SLE patients may develop LN. The primary goal of LN treatment is to preserve kidney function, reduce mortality, and improve the patient's quality of life while minimizing treatment-related adverse events. A timely response to therapy, as indicated by a reduction in proteinuria, may predict long-term outcomes, including the risk of SLE flares, end-stage kidney disease, and mortality. In the United States, voclosporin received FDA approval in 2021 for treating active LN in adults, combined with background immunosuppressive therapy. This CME activity overviews the indications, actions, and contraindications for voclosporin. It also emphasizes the mechanism of action, adverse event profile, and key factors such as dosing, pharmacokinetics, contraindications, and monitoring that are essential for healthcare team members involved in treating patients with lupus nephritis using voclosporin."}
{"id": "article-155737_1", "title": "Voclosporin -- Continuing Education Activity", "content": "Objectives: Identify the signs and symptoms of LWE through careful patient assessment and evaluation. Develop and implement appropriate treatment strategies and interventions tailored to the individual patient's needs. Select and prescribe appropriate topical anti-inflammatories and ocular surface lubricants based on the severity and characteristics of LWE. Effectively communicate with the patient, as well as other members of the healthcare team, to ensure a comprehensive understanding of LWE and its management plan. Access free multiple choice questions on this topic.", "contents": "Voclosporin -- Continuing Education Activity. Objectives: Identify the signs and symptoms of LWE through careful patient assessment and evaluation. Develop and implement appropriate treatment strategies and interventions tailored to the individual patient's needs. Select and prescribe appropriate topical anti-inflammatories and ocular surface lubricants based on the severity and characteristics of LWE. Effectively communicate with the patient, as well as other members of the healthcare team, to ensure a comprehensive understanding of LWE and its management plan. Access free multiple choice questions on this topic."}
{"id": "article-155737_2", "title": "Voclosporin -- Indications", "content": "Voclosporin is a novel calcineurin inhibitor (CNI) that was developed and approved for treating lupus nephritis (LN). Voclosporin is a cyclosporine A analog with a modification of the functional group on the amino acid 1 residue. [1] The drug has an improved pharmacokinetic profile compared to other CNIs, such as cyclosporine, tacrolimus, and sirolimus. [1] [2]", "contents": "Voclosporin -- Indications. Voclosporin is a novel calcineurin inhibitor (CNI) that was developed and approved for treating lupus nephritis (LN). Voclosporin is a cyclosporine A analog with a modification of the functional group on the amino acid 1 residue. [1] The drug has an improved pharmacokinetic profile compared to other CNIs, such as cyclosporine, tacrolimus, and sirolimus. [1] [2]"}
{"id": "article-155737_3", "title": "Voclosporin -- Indications", "content": "Voclosporin was approved by the Food and Drug Administration (FDA) in the USA on January 22, 2021, specifically for the treatment of adults with biopsy-proven lupus nephritis (LN) class III, IV, or V (class V alone or in combination with class III or IV). It is intended to be utilized in conjunction with background immunosuppressive therapy as part of the treatment regimen for LN. [3]", "contents": "Voclosporin -- Indications. Voclosporin was approved by the Food and Drug Administration (FDA) in the USA on January 22, 2021, specifically for the treatment of adults with biopsy-proven lupus nephritis (LN) class III, IV, or V (class V alone or in combination with class III or IV). It is intended to be utilized in conjunction with background immunosuppressive therapy as part of the treatment regimen for LN. [3]"}
{"id": "article-155737_4", "title": "Voclosporin -- Indications", "content": "In Europe, voclosporin was approved by European Medicines Agency (EMA) on September 15, 2022. It is recommended by the European League Against Rheumatism and European Renal Association (EULAR/ERA) as an addition to a background regimen of mycophenolate mofetil and low-dose glucocorticoids in patients with LN. [4] The addition of voclosporin to background therapy significantly increases the chances of achieving the target urine/protein creatinine ratio at 3, 6, and 12 months. [1]", "contents": "Voclosporin -- Indications. In Europe, voclosporin was approved by European Medicines Agency (EMA) on September 15, 2022. It is recommended by the European League Against Rheumatism and European Renal Association (EULAR/ERA) as an addition to a background regimen of mycophenolate mofetil and low-dose glucocorticoids in patients with LN. [4] The addition of voclosporin to background therapy significantly increases the chances of achieving the target urine/protein creatinine ratio at 3, 6, and 12 months. [1]"}
{"id": "article-155737_5", "title": "Voclosporin -- Mechanism of Action", "content": "Voclosporin is an oral CNI that binds cyclophilin A in T-cells. [2] The drug molecule has a cyclic undecapeptide structure of 11 amino acids, originally isolated from a fungus species named Beauveria nivea. [5] [6] There is an additional single carbon extension to the amino acid-1 position. [2] This structural change results in a molecule with higher binding potency to cyclophilin A and increased inhibition of calcineurin. [2] [7] The voclosporin-cyclophilin binding competitively inhibits calcineurin from dephosphorylating the nuclear factor of activated T-cells (NFAT-P) to the nuclear factor of activated T-cells (NFAT). [2]", "contents": "Voclosporin -- Mechanism of Action. Voclosporin is an oral CNI that binds cyclophilin A in T-cells. [2] The drug molecule has a cyclic undecapeptide structure of 11 amino acids, originally isolated from a fungus species named Beauveria nivea. [5] [6] There is an additional single carbon extension to the amino acid-1 position. [2] This structural change results in a molecule with higher binding potency to cyclophilin A and increased inhibition of calcineurin. [2] [7] The voclosporin-cyclophilin binding competitively inhibits calcineurin from dephosphorylating the nuclear factor of activated T-cells (NFAT-P) to the nuclear factor of activated T-cells (NFAT). [2]"}
{"id": "article-155737_6", "title": "Voclosporin -- Mechanism of Action", "content": "Inhibition of this critical metabolic step precludes NFAT from activating the translation and transcription of various cytokines produced by T-helper-1 cells, including interleukin-2 (IL-2). IL-2 is a T-cell growth factor vital for the proliferation of T cells and for the generation of effector and memory cells. [2] [8] [9] The inhibited production of IL-2 prevents the proliferation and differentiation of cytotoxic and other effector T cells. [7] [9]", "contents": "Voclosporin -- Mechanism of Action. Inhibition of this critical metabolic step precludes NFAT from activating the translation and transcription of various cytokines produced by T-helper-1 cells, including interleukin-2 (IL-2). IL-2 is a T-cell growth factor vital for the proliferation of T cells and for the generation of effector and memory cells. [2] [8] [9] The inhibited production of IL-2 prevents the proliferation and differentiation of cytotoxic and other effector T cells. [7] [9]"}
{"id": "article-155737_7", "title": "Voclosporin -- Mechanism of Action", "content": "Activated calcineurin dephosphorylates synaptopodin which is then metabolized by a lysosomal protease. [10] This breakdown ultimately results in the destabilization of the podocyte cytoskeleton and increases proteinuria. [7] [10] Voclosporin, by inhibiting this dephosphorylation pathway, promotes actin cytoskeleton stabilization of the podocytes and thus reduces proteinuria. [8] Voclosporin inhibits the dephosphorylation pathway by binding the phosphorylated synaptopodin with the 14-3-3 protein. [2] [7] [10]", "contents": "Voclosporin -- Mechanism of Action. Activated calcineurin dephosphorylates synaptopodin which is then metabolized by a lysosomal protease. [10] This breakdown ultimately results in the destabilization of the podocyte cytoskeleton and increases proteinuria. [7] [10] Voclosporin, by inhibiting this dephosphorylation pathway, promotes actin cytoskeleton stabilization of the podocytes and thus reduces proteinuria. [8] Voclosporin inhibits the dephosphorylation pathway by binding the phosphorylated synaptopodin with the 14-3-3 protein. [2] [7] [10]"}
{"id": "article-155737_8", "title": "Voclosporin -- Mechanism of Action", "content": "The modification of amino acid-1 changes the primary site of metabolism to the amino acid-9 position. The modification results in a lower degree of competitive inhibition and a low metabolite load. [5] [11] This favorable metabolic profile also improves serum drug levels in a dose-proportional manner over a wide therapeutic range. This particular property means that therapeutic drug monitoring is not required for voclosporin. [5]", "contents": "Voclosporin -- Mechanism of Action. The modification of amino acid-1 changes the primary site of metabolism to the amino acid-9 position. The modification results in a lower degree of competitive inhibition and a low metabolite load. [5] [11] This favorable metabolic profile also improves serum drug levels in a dose-proportional manner over a wide therapeutic range. This particular property means that therapeutic drug monitoring is not required for voclosporin. [5]"}
{"id": "article-155737_9", "title": "Voclosporin -- Mechanism of Action -- Pharmacokinetics", "content": "The major circulating component is voclosporin. A major metabolite of voclosporin with approximately 8-fold less potency than the parent molecule represented about 16.7% of total exposure in whole human blood. [3] Around 99% of the drug is metabolized via cytochrome P450 3A4 (CYP3A4) isoform and excreted in feces, as confirmed after administration of radiolabeled voclosporin. [2] [3]", "contents": "Voclosporin -- Mechanism of Action -- Pharmacokinetics. The major circulating component is voclosporin. A major metabolite of voclosporin with approximately 8-fold less potency than the parent molecule represented about 16.7% of total exposure in whole human blood. [3] Around 99% of the drug is metabolized via cytochrome P450 3A4 (CYP3A4) isoform and excreted in feces, as confirmed after administration of radiolabeled voclosporin. [2] [3]"}
{"id": "article-155737_10", "title": "Voclosporin -- Mechanism of Action -- Pharmacokinetics", "content": "After six days of twice daily dosing, voclosporin can achieve steady-state concentrations. [3] The maximum concentration (Cmax) of voclosporin can be reached within 1 to 4 hours if taken on an empty stomach. [3] The pharmacokinetics of voclosporin is not influenced by age, gender, body weight, race, total bilirubin, and serum albumin in a clinically relevant manner. [3] There was no significant lag between the interval taken to reach maximum voclosporin concentrations and the time taken for maximum inhibition of calcineurin. [3] [12]", "contents": "Voclosporin -- Mechanism of Action -- Pharmacokinetics. After six days of twice daily dosing, voclosporin can achieve steady-state concentrations. [3] The maximum concentration (Cmax) of voclosporin can be reached within 1 to 4 hours if taken on an empty stomach. [3] The pharmacokinetics of voclosporin is not influenced by age, gender, body weight, race, total bilirubin, and serum albumin in a clinically relevant manner. [3] There was no significant lag between the interval taken to reach maximum voclosporin concentrations and the time taken for maximum inhibition of calcineurin. [3] [12]"}
{"id": "article-155737_11", "title": "Voclosporin -- Mechanism of Action -- Pharmacokinetics", "content": "When administered with low- or high-fat meals in healthy adults, Cmax decreases by 29% to 53%. [3] Voclosporin distributes extensively in red blood cells. The distribution between whole blood and plasma is dependent on concentration and temperature. [3] Given voclosporin\u2019s high protein binding of 97%, its apparent volume of distribution of 2154 Liters. Voclosporin\u2019s mean apparent clearance is 63.6 L/h at steady-state with a mean terminal half-life of around 30 hours. [3]", "contents": "Voclosporin -- Mechanism of Action -- Pharmacokinetics. When administered with low- or high-fat meals in healthy adults, Cmax decreases by 29% to 53%. [3] Voclosporin distributes extensively in red blood cells. The distribution between whole blood and plasma is dependent on concentration and temperature. [3] Given voclosporin\u2019s high protein binding of 97%, its apparent volume of distribution of 2154 Liters. Voclosporin\u2019s mean apparent clearance is 63.6 L/h at steady-state with a mean terminal half-life of around 30 hours. [3]"}
{"id": "article-155737_12", "title": "Voclosporin -- Administration", "content": "Voclosporin is dosed and administered in the following manner: In adults with active lupus nephritis, when combined with background immunosuppressive therapy: 23.7 mg twice daily by mouth. To ensure adequate absorption, voclosporin must be taken on an empty stomach. [13] Dose adjustments may be necessary for patients with renal dysfunction and are as follows:", "contents": "Voclosporin -- Administration. Voclosporin is dosed and administered in the following manner: In adults with active lupus nephritis, when combined with background immunosuppressive therapy: 23.7 mg twice daily by mouth. To ensure adequate absorption, voclosporin must be taken on an empty stomach. [13] Dose adjustments may be necessary for patients with renal dysfunction and are as follows:"}
{"id": "article-155737_13", "title": "Voclosporin -- Administration", "content": "If eGFR is <60 mL/min/1.73 m 2 and reduced from baseline by >20% and <30%, the dose should be reduced by 7.9 mg twice daily. [2] Upon re-assessing the eGFR within\u00a02 weeks, if it is still reduced from baseline by >20%, reduce the dose again by 7.9 mg twice daily. [3] If eGFR is <60 mL/min/1.73 m 2 and reduced from baseline by >30%, voclosporin should be discontinued. [2] [3] For patients with a decrease in dose due to eGFR, consider increasing the dose by 7.9 mg twice daily for each eGFR measurement that is \u226580% of baseline; do not exceed the starting dose. If voclosporin is used in patients with severe renal impairment at baseline (creatinine clearance <30 mL/min the recommended starting dose is 15.8 mg twice a day. [2] [3] In patients with end-stage renal disease (ESRD) with or without hemodialysis, the pharmacokinetics of voclosporin is unknown. [2] [3] Dose adjustments may be necessary for patients with hepatic dysfunction and are as follows:", "contents": "Voclosporin -- Administration. If eGFR is <60 mL/min/1.73 m 2 and reduced from baseline by >20% and <30%, the dose should be reduced by 7.9 mg twice daily. [2] Upon re-assessing the eGFR within\u00a02 weeks, if it is still reduced from baseline by >20%, reduce the dose again by 7.9 mg twice daily. [3] If eGFR is <60 mL/min/1.73 m 2 and reduced from baseline by >30%, voclosporin should be discontinued. [2] [3] For patients with a decrease in dose due to eGFR, consider increasing the dose by 7.9 mg twice daily for each eGFR measurement that is \u226580% of baseline; do not exceed the starting dose. If voclosporin is used in patients with severe renal impairment at baseline (creatinine clearance <30 mL/min the recommended starting dose is 15.8 mg twice a day. [2] [3] In patients with end-stage renal disease (ESRD) with or without hemodialysis, the pharmacokinetics of voclosporin is unknown. [2] [3] Dose adjustments may be necessary for patients with hepatic dysfunction and are as follows:"}
{"id": "article-155737_14", "title": "Voclosporin -- Administration", "content": "In patients with mild and moderate hepatic impairment (Child-Pugh A and Child-Pugh B), the recommended dose is 15.8 mg twice daily. Voclosporin is not recommended in patients with severe hepatic impairment (Child-Pugh C).", "contents": "Voclosporin -- Administration. In patients with mild and moderate hepatic impairment (Child-Pugh A and Child-Pugh B), the recommended dose is 15.8 mg twice daily. Voclosporin is not recommended in patients with severe hepatic impairment (Child-Pugh C)."}
{"id": "article-155737_15", "title": "Voclosporin -- Administration -- Drug Interactions", "content": "Voclosporin is a CYP3A4 substrate. When co-administered with other medications that are moderate or potent CYP3A4 inhibitors, it reduces clearance and increases voclosporin levels. The increased levels can increase the risk of voclosporin-associated adverse reactions. [3]", "contents": "Voclosporin -- Administration -- Drug Interactions. Voclosporin is a CYP3A4 substrate. When co-administered with other medications that are moderate or potent CYP3A4 inhibitors, it reduces clearance and increases voclosporin levels. The increased levels can increase the risk of voclosporin-associated adverse reactions. [3]"}
{"id": "article-155737_16", "title": "Voclosporin -- Administration -- Drug Interactions", "content": "AReducingthe dose of voclosporin is recommended when co-administered with moderate CYP3A4 inhibitors such as verapamil, fluconazole, and diltiazem. [7]", "contents": "Voclosporin -- Administration -- Drug Interactions. AReducingthe dose of voclosporin is recommended when co-administered with moderate CYP3A4 inhibitors such as verapamil, fluconazole, and diltiazem. [7]"}
{"id": "article-155737_17", "title": "Voclosporin -- Administration -- Drug Interactions", "content": "When voclosporin is co-administered with moderate or strong CYP3A4 inducers, the combination increases voclosporin metabolism, reducing the efficacy of voclosporin. [3] [7]", "contents": "Voclosporin -- Administration -- Drug Interactions. When voclosporin is co-administered with moderate or strong CYP3A4 inducers, the combination increases voclosporin metabolism, reducing the efficacy of voclosporin. [3] [7]"}
{"id": "article-155737_18", "title": "Voclosporin -- Administration -- Drug Interactions", "content": "Voclosporin is an inhibitor of P-glycoprotein (P-gp). Hence, caution is required upon co-administration with other P-gp inhibitors such as verapamil, sertraline, erythromycin, and reserpine. If P-gp substrates with a narrow therapeutic index, such as digoxin, are co-administered with voclosporin, then a dose reduction of P-gb substrates may be required. [2] [14]", "contents": "Voclosporin -- Administration -- Drug Interactions. Voclosporin is an inhibitor of P-glycoprotein (P-gp). Hence, caution is required upon co-administration with other P-gp inhibitors such as verapamil, sertraline, erythromycin, and reserpine. If P-gp substrates with a narrow therapeutic index, such as digoxin, are co-administered with voclosporin, then a dose reduction of P-gb substrates may be required. [2] [14]"}
{"id": "article-155737_19", "title": "Voclosporin -- Administration -- Drug Interactions", "content": "There is no clinically significant interaction between voclosporin and mycophenolate mofetil. There is no necessity for dose adjustment when these medications are administered simultaneously. [4]", "contents": "Voclosporin -- Administration -- Drug Interactions. There is no clinically significant interaction between voclosporin and mycophenolate mofetil. There is no necessity for dose adjustment when these medications are administered simultaneously. [4]"}
{"id": "article-155737_20", "title": "Voclosporin -- Adverse Effects", "content": "Voclosporin, similar to other CNIs, can cause acute and chronic nephrotoxicity. The major adverse effect of voclosporin is reduced glomerular filtration rate. Nephrotoxicity is usually dose-dependent and can be influenced by drug\u2013drug interactions and intracellular concentrations. Acute nephrotoxicity can be caused by a reversible glomerular filtration rate (GFR) decrease. Chronic nephrotoxicity can be marked by nonspecific arteriolar lesions, focal and segmental and global glomerular sclerosis, patchy interstitial fibrosis, and tubular atrophy, which can progress to irreversible lesions. [7]", "contents": "Voclosporin -- Adverse Effects. Voclosporin, similar to other CNIs, can cause acute and chronic nephrotoxicity. The major adverse effect of voclosporin is reduced glomerular filtration rate. Nephrotoxicity is usually dose-dependent and can be influenced by drug\u2013drug interactions and intracellular concentrations. Acute nephrotoxicity can be caused by a reversible glomerular filtration rate (GFR) decrease. Chronic nephrotoxicity can be marked by nonspecific arteriolar lesions, focal and segmental and global glomerular sclerosis, patchy interstitial fibrosis, and tubular atrophy, which can progress to irreversible lesions. [7]"}
{"id": "article-155737_21", "title": "Voclosporin -- Adverse Effects", "content": "Hypertension is a common adverse effect of voclosporin; it can be explained by the vasoconstrictive effect of voclosporin on afferent pre-glomerular arterioles.\u00a0Hypertension also contributes to decreased eGFR and subsequent salt and water retention. Arterial hypertension is less severe with voclosporin when compared to other CNIs. [2] [7] [11] Voclosporin can cause neurotoxicity, including posterior reversible encephalopathy syndrome (PRES), delirium, seizure, coma, tremors, paresthesia, headache, and mental status changes. [7]", "contents": "Voclosporin -- Adverse Effects. Hypertension is a common adverse effect of voclosporin; it can be explained by the vasoconstrictive effect of voclosporin on afferent pre-glomerular arterioles.\u00a0Hypertension also contributes to decreased eGFR and subsequent salt and water retention. Arterial hypertension is less severe with voclosporin when compared to other CNIs. [2] [7] [11] Voclosporin can cause neurotoxicity, including posterior reversible encephalopathy syndrome (PRES), delirium, seizure, coma, tremors, paresthesia, headache, and mental status changes. [7]"}
{"id": "article-155737_22", "title": "Voclosporin -- Adverse Effects", "content": "Although clinically apparent acute liver injury with jaundice has not been classically linked to voclosporin, it can be associated with a low rate of transient serum enzyme elevations during treatment. [6]", "contents": "Voclosporin -- Adverse Effects. Although clinically apparent acute liver injury with jaundice has not been classically linked to voclosporin, it can be associated with a low rate of transient serum enzyme elevations during treatment. [6]"}
{"id": "article-155737_23", "title": "Voclosporin -- Adverse Effects", "content": "Electrolyte disturbances of hyperkalemia and hypomagnesemia can occur with the administration of calcineurin inhibitors, including voclosporin. Hypomagnesemia can be caused by reduced renal reabsorption of magnesium and chronic renal magnesium wasting. Due to the inhibition of calcineurin, there is reduced expression of Na-K-2Cl-cotransporter on the tubular epithelial cells, which plays a role in hyperkalemia. These electrolyte abnormalities may be responsible for voclosporin prolonging QTc interval. Dose-dependent QTc prolongation was noted after a single dose of voclosporin 0.5\u00a0to 4.5 mg/kg (which is up to 9-fold higher than the therapeutic dose). [2] [12] [13]", "contents": "Voclosporin -- Adverse Effects. Electrolyte disturbances of hyperkalemia and hypomagnesemia can occur with the administration of calcineurin inhibitors, including voclosporin. Hypomagnesemia can be caused by reduced renal reabsorption of magnesium and chronic renal magnesium wasting. Due to the inhibition of calcineurin, there is reduced expression of Na-K-2Cl-cotransporter on the tubular epithelial cells, which plays a role in hyperkalemia. These electrolyte abnormalities may be responsible for voclosporin prolonging QTc interval. Dose-dependent QTc prolongation was noted after a single dose of voclosporin 0.5\u00a0to 4.5 mg/kg (which is up to 9-fold higher than the therapeutic dose). [2] [12] [13]"}
{"id": "article-155737_24", "title": "Voclosporin -- Adverse Effects", "content": "The exact association between pure red cell aplasia (PRCA) and voclosporin is unknown. If a patient develops PRCA while on treatment with voclosporin, the discontinuation of voclosporin should be considered. Voclosporin may increase the risk of developing lymphomas and malignancies predominantly of the skin. [4] [7] Other adverse effects reported with voclosporin are as follows, and these can be approached on a case-by-case basis, weighing the benefits and the risks. Diarrhea Nausea with vomiting Headache Anemia Cough Increased risk of infections such as upper respiratory tract infections Peripheral edema Alopecia Insomnia", "contents": "Voclosporin -- Adverse Effects. The exact association between pure red cell aplasia (PRCA) and voclosporin is unknown. If a patient develops PRCA while on treatment with voclosporin, the discontinuation of voclosporin should be considered. Voclosporin may increase the risk of developing lymphomas and malignancies predominantly of the skin. [4] [7] Other adverse effects reported with voclosporin are as follows, and these can be approached on a case-by-case basis, weighing the benefits and the risks. Diarrhea Nausea with vomiting Headache Anemia Cough Increased risk of infections such as upper respiratory tract infections Peripheral edema Alopecia Insomnia"}
{"id": "article-155737_25", "title": "Voclosporin -- Contraindications", "content": "The co-administration of voclosporin with potent CYP3A4 inhibitors, for example, ketoconazole, itraconazole, and clarithromycin, are contraindicated. [15] In patients with eGFR <45 mL/min/1.73 m 2 , using voclosporin is contraindicated unless benefits exceed risks. [3] [15] Voclosporin is not recommended in patients with hypertension with a baseline blood pressure of >165/105 mm Hg. [3] [7] Although there is not much data about the use of voclosporin in pregnant women and lactating women, voclosporin formulation contains alcohol, and the current recommendation is that voclosporin should be avoided in pregnant and lactating patients. [16]", "contents": "Voclosporin -- Contraindications. The co-administration of voclosporin with potent CYP3A4 inhibitors, for example, ketoconazole, itraconazole, and clarithromycin, are contraindicated. [15] In patients with eGFR <45 mL/min/1.73 m 2 , using voclosporin is contraindicated unless benefits exceed risks. [3] [15] Voclosporin is not recommended in patients with hypertension with a baseline blood pressure of >165/105 mm Hg. [3] [7] Although there is not much data about the use of voclosporin in pregnant women and lactating women, voclosporin formulation contains alcohol, and the current recommendation is that voclosporin should be avoided in pregnant and lactating patients. [16]"}
{"id": "article-155737_26", "title": "Voclosporin -- Monitoring", "content": "The patient's blood pressure should also be recorded before treatment initiation and monitored biweekly for the first month of treatment. After which, it should be monitored as indicated clinically. [5] [7]", "contents": "Voclosporin -- Monitoring. The patient's blood pressure should also be recorded before treatment initiation and monitored biweekly for the first month of treatment. After which, it should be monitored as indicated clinically. [5] [7]"}
{"id": "article-155737_27", "title": "Voclosporin -- Monitoring", "content": "An accurate baseline estimated glomerular filtration rate (eGFR) should be established before initiating voclosporin, and eGFR should be assessed every\u00a02 weeks for the first month of treatment and every\u00a04 weeks after that. [13]", "contents": "Voclosporin -- Monitoring. An accurate baseline estimated glomerular filtration rate (eGFR) should be established before initiating voclosporin, and eGFR should be assessed every\u00a02 weeks for the first month of treatment and every\u00a04 weeks after that. [13]"}
{"id": "article-155737_28", "title": "Voclosporin -- Monitoring", "content": "Voclosporin and mycophenolate mofetil (MMF) can be administered concomitantly without adjusting the dose of MMF. There is no risk of the emergence of MMF-related adverse effects following the discontinuation of voclosporin. [4]", "contents": "Voclosporin -- Monitoring. Voclosporin and mycophenolate mofetil (MMF) can be administered concomitantly without adjusting the dose of MMF. There is no risk of the emergence of MMF-related adverse effects following the discontinuation of voclosporin. [4]"}
{"id": "article-155737_29", "title": "Voclosporin -- Toxicity", "content": "In the event of overdose or toxicity, there are currently no reversal agents approved for voclosporin\u00a0by the FDA. The FDA-boxed warnings include an increased risk of developing serious infections and malignancies.", "contents": "Voclosporin -- Toxicity. In the event of overdose or toxicity, there are currently no reversal agents approved for voclosporin\u00a0by the FDA. The FDA-boxed warnings include an increased risk of developing serious infections and malignancies."}
{"id": "article-155737_30", "title": "Voclosporin -- Enhancing Healthcare Team Outcomes", "content": "The management of autoimmune diseases, such as SLE/LN, is a complex process that imposes a significant cost burden on both patients and the healthcare system. Voclosporin, a novel immunosuppressive agent, is used in combination with background immunosuppressive therapy for patients with lupus nephritis. The utilization of background immunosuppressive therapies in conjunction with voclosporin is a critical aspect of LN management.", "contents": "Voclosporin -- Enhancing Healthcare Team Outcomes. The management of autoimmune diseases, such as SLE/LN, is a complex process that imposes a significant cost burden on both patients and the healthcare system. Voclosporin, a novel immunosuppressive agent, is used in combination with background immunosuppressive therapy for patients with lupus nephritis. The utilization of background immunosuppressive therapies in conjunction with voclosporin is a critical aspect of LN management."}
{"id": "article-155737_31", "title": "Voclosporin -- Enhancing Healthcare Team Outcomes", "content": "To ensure the best possible outcomes for patients, an interprofessional healthcare team comprising various specialties is essential. Despite the improved pharmacodynamics of voclosporin compared to previous calcineurin inhibitors (CNIs), it can still lead to severe adverse effects. Therefore, regular patient visits and frequent monitoring of vital signs and laboratory tests are crucial to prevent potential complications. Primary care providers, including\u00a0advanced practice practitioners,\u00a0should be well-informed about significant adverse effects and maintain open communication with rheumatologists and nephrologists to address any concerns that may arise.", "contents": "Voclosporin -- Enhancing Healthcare Team Outcomes. To ensure the best possible outcomes for patients, an interprofessional healthcare team comprising various specialties is essential. Despite the improved pharmacodynamics of voclosporin compared to previous calcineurin inhibitors (CNIs), it can still lead to severe adverse effects. Therefore, regular patient visits and frequent monitoring of vital signs and laboratory tests are crucial to prevent potential complications. Primary care providers, including\u00a0advanced practice practitioners,\u00a0should be well-informed about significant adverse effects and maintain open communication with rheumatologists and nephrologists to address any concerns that may arise."}
{"id": "article-155737_32", "title": "Voclosporin -- Enhancing Healthcare Team Outcomes", "content": "Given the potential for drug interactions, collaborative patient care involving pharmacists is paramount. Accurate and comprehensive medication reconciliation, along with verification of the appropriate dose adjusted for creatinine clearance, should be conducted by pharmacists. If any discrepancies are noted, they should promptly communicate them to other members of the healthcare team.", "contents": "Voclosporin -- Enhancing Healthcare Team Outcomes. Given the potential for drug interactions, collaborative patient care involving pharmacists is paramount. Accurate and comprehensive medication reconciliation, along with verification of the appropriate dose adjusted for creatinine clearance, should be conducted by pharmacists. If any discrepancies are noted, they should promptly communicate them to other members of the healthcare team."}
{"id": "article-155737_33", "title": "Voclosporin -- Enhancing Healthcare Team Outcomes", "content": "Close monitoring for adverse effects is necessary for all patients receiving voclosporin, and nurses often play a key role in being the first to receive reports of adverse events from patients. This information can then be shared with other members of the healthcare team for collaborative decision-making regarding further steps. Social workers have a crucial role in identifying barriers to care, including financial constraints that may hinder medication affordability. The social work team can provide the necessary resources and support to assist patients in overcoming these challenges.", "contents": "Voclosporin -- Enhancing Healthcare Team Outcomes. Close monitoring for adverse effects is necessary for all patients receiving voclosporin, and nurses often play a key role in being the first to receive reports of adverse events from patients. This information can then be shared with other members of the healthcare team for collaborative decision-making regarding further steps. Social workers have a crucial role in identifying barriers to care, including financial constraints that may hinder medication affordability. The social work team can provide the necessary resources and support to assist patients in overcoming these challenges."}
{"id": "article-155737_34", "title": "Voclosporin -- Enhancing Healthcare Team Outcomes", "content": "In summary, the use of voclosporin in the treatment of lupus nephritis requires an interprofessional healthcare team consisting of physicians, physician extenders, nurses, pharmacists, and social workers. Although team members come from various disciplines, effective collaboration and communication are essential to achieve optimal outcomes for patients.[Level 5]", "contents": "Voclosporin -- Enhancing Healthcare Team Outcomes. In summary, the use of voclosporin in the treatment of lupus nephritis requires an interprofessional healthcare team consisting of physicians, physician extenders, nurses, pharmacists, and social workers. Although team members come from various disciplines, effective collaboration and communication are essential to achieve optimal outcomes for patients.[Level 5]"}
{"id": "article-155737_35", "title": "Voclosporin -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Voclosporin -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}